Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. Johnson & Johnson has announced the FDA’s approval of a first-of ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...

Spravato (esketamine) is a nasal spray used for depression and was approved by the FDA in 2019. It is specifically for treatment-resistant depression, meaning depression symptoms that have not ...

Spravato had been cleared in the United States ... coli June 5 (UPI) -- Some packages of organic ground beef sold at Whole Foods stores across the country may be contaminated with E.

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

On Tuesday, the government agency announced Spravato nasal spray, also known as esketamine, can now be used "for the treatment of depression in adults who have tried other antidepressant ...

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is ...

Spravato (esketamine) is a prescription drug that’s approved to treat certain forms of depression. Esketamine comes as a nasal spray that you inhale. Specifically, Spravato is approved by the ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers. “A lot of people didn’t think it would work ...

It is a legal medical treatment. The 34-year-old doctor from Denver is taking Spravato, a medicine derived from club-drug ketamine that is approved for treating his depression.

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.